Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 11/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | GLA | P06280 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19437519 | 0.89 | STING1 (0.62) | STING1KDM4EGLAGAAALDH1A1 | |
| SCHEMBL19437553 | 0.84 | STING1 (0.57) | STING1KDM4EGLAALDH1A1HPGD | |
| SCHEMBL22135066 | 0.83 | STING1 (0.57) | STING1 | |
| SCHEMBL28522082 | 0.82 | STING1 (0.56) | STING1KDM4EGAA | |
| SCHEMBL19436475 | 0.80 | BACE1 (0.46) | STING1KMT2A | |
| SCHEMBL19436532 | 0.79 | STING1 (0.68) | STING1 | |
| SCHEMBL19437676 | 0.79 | STING1 (0.85) | STING1 | |
| Bromide SCHEMBL23327843 | 0.79 | STING1 (0.67) | STING1 | |
| Bromide SCHEMBL29619902 | 0.79 | STING1 (0.67) | STING1 | |
| SCHEMBL22150070 | 0.78 | STING1 (0.75) | STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975287-B2 | Heterocyclic amides useful as protein modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2021-04-13 | — | — | US | disclosed |
| US-20200325126-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-15 | — | — | US | disclosed |
| EP-3440072-B1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325126-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | ARGLU1, G3BP1, G3BP2 | STING1 2510/4885KDM4E 2147/4885GLA 3099/4885 |
| US-10975287-B2 | Heterocyclic amides useful as protein modulators | ARGLU1, G3BP1, G3BP2 | STING1 2510/4885KDM4E 2147/4885GLA 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.